Last updated today
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease.Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters.Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to significantly reduce liver fat content as well as improve metabolic parameters associated with fatty liver disease.
Last updated today
Coming soon.
No recent security news.
More security reports
Cybersecurity & Risk Management Library
The ultimate guide to attack surface and third-party risk management – actionable advice for security teams, managers, and executives.
Breaches
Security research and global news about data breaches.
Explore resources
Third-party risk management
Articles, news, and research on third-party risk management.
Explore resources
Attack Surface Management
Articles, news, and research on attack surface management.
Explore resources
Cybersecurity
Articles, news, and research on cybersecurity.
Explore resources
Leader in Third Party & Supplier Risk Management Software
See how UpGuard shapes up against other platforms in the market.
"This is some text inside of a div block."
Free instant security score
How secure is your organization?
Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
- Instant insights you can act on immediately
- Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.